We designed the study to identify the clinical and dose-volumetric parameters associated with the risk of Child-Pugh score elevation in hepatocellular carcinoma patients treated with conformal radiation therapy.
Methods and study design
All 161 hepatocellular carcinoma patients in the study underwent 4D-computed tomography simulation, and a dose-volume histogram was generated after radiotherapy planning. Patients who had an elevated Child-Pugh (e-CP) score of 2 or more without progressive disease within 3 months were defined as e-CP positive.
Results
Twenty-six of 142 patients without progressive disease were e-CP positive. Pretreatment Child-Pugh class, further treatment within 30 days of radiotherapy, lymph node metastasis, mean liver dose, V20 Gy, V25 Gy, and V30 Gy were significantly correlated with e-CP positivity. The e-CP developed in 13 of 106 patients (12.3%) with V30 Gy of ≤28.1% and in 13 of 36 patients (36.1%) with V30 Gy >28.1% (P = 0.001).
Conclusions
Our data demonstrate that mean liver dose, V10 Gy, V20 Gy, V25 Gy, and V30 Gy are independent dose-volumetric predictors for e-CP positivity in hepatocellular carcinoma patients treated with conformal radiation therapy. V30 Gy should be limited to less than 28.1% to minimize the risk of e-CP.
ParkW., LimD.H., PaikS.W., KohK.C., ChoiM.S., ParkC.K., YooB.C., LeeJ.E., KangM.K., ParkY.J., NamH.R., AhnY.C., HuhS.J.: Local radiotherapy for patients with unresectable hepatocellular carcinoma.Int J Radiat Oncol Biol Phys, 61: 1143–1150, 2005.
3.
SeongJ., ParkH.C., HanK.H., LeeD.Y., LeeJ.T., ChonC.Y., MoonY.M., SuhC.O.: Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization.Int J Radiat Oncol Biol Phys, 47: 1331–1335, 2000.
4.
RusthovenK.E., KavanaghB.D., CardenesH., StieberV.W., BurriS.H., FeigenbergS.J., ChidelM.A., PughT.J., FranklinW., KaneM., GasparL.E., SchefterT.E.: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.J Clin Oncol, 27: 1572–1578, 2009.
5.
TseR.V., HawkinsM., LockwoodG., KimJ.J., CummingsB., KnoxJ., ShermanM., DawsonL.A.: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.J Clin Oncol, 26: 657–664, 2008.
6.
FerenciP., FriedM., LabrecqueD., BruixJ., ShermanM., OmataM., HeathcoteJ., PiratsivuthT., KewM., OtegbayoJ.A., ZhengS.S., SarinS., HamidS., ModawiS.B., FleigW., FedailS., ThomsonA., KhanA., MalfertheinerP., LauG., CarilloF.J., KrabshuisJ., Le MairA.: World gastroenterology organisation guideline. Hepatocellular carcinoma (HCC): a global perspective.J Gastrointestin Liver Dis, 19: 311–317, 2010.
7.
SongP., TangW., TamuraS., HasegawaK., SugawaraY., DongJ., KokudoN.: The management of hepatocellular carcinoma in Asia: A guideline combining quantitative and qualitative evaluation.Biosci Trends, 4: 283–287, 2010.
8.
LawrenceT.S., RobertsonJ.M., AnscherM.S., JirtleR.L., EnsmingerW.D., FajardoL.F.: Hepatic toxicity resulting from cancer treatment.Int J Radiat Oncol Biol Phys, 31: 1237–1248, 1995.
9.
DawsonL.A., NormolleD., BalterJ.M., McGinnC.J., LawrenceT.S., Ten HakenR.K.: Analysis of radiation-induced liver disease using the Lyman NTCP model.Int J Radiat Oncol Biol Phys, 53: 810–821, 2002.
10.
LiangS.X., HuangX.B., ZhuX.D., ZhangW.D., CaiL., HuangH.Z., LiY.F., ChenL., LiuM.Z.: Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child-Pugh grade A cirrhosis.Radiother Oncol, 98: 265–269, 2011.
11.
ChengJ.C., WuJ.K., HuangC.M., LiuH.S., HuangD.Y., ChengS.H., TsaiS.Y., JianJ.J., LinY.M., ChengT.I., HorngC.F., HuangA.T.: Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication.Int J Radiat Oncol Biol Phys, 54: 156–162, 2002.
12.
XuL.T., ZhouZ.H., LinJ.H., ChenZ., WangK., WangP., ZhuX.Y., ShenY.H., MengZ.Q., LiuL.M.: Clinical study of transarterial chemoembolization combined with 3–dimensional conformal radiotherapy for hepatocellular carcinoma.Eur J Surg Oncol, 37: 245–251, 2011.
HiguchiT., KikuchiM., OkazakiM.: Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases.Cancer, 73: 2259–2267, 1994.
17.
OhD., Lim doH., ParkH.C., PaikS.W., KohK.C., LeeJ.H., ChoiM.S., YooB.C., LimH.K., LeeW.J., RhimH., ShinS.W., ParkK.B.: Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity.Am J Clin Oncol, 33: 370–375, 2010.
ChoiS.B., KimK.S., ParkY.N., ChoiJ.S., LeeW.J., SeongJ., HanK.H., LeeJ.T.: The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size.J Korean Med Sci, 24: 242–247, 2009.
20.
SonS.H., ChoiB.O., RyuM.R., KangY.N., JangJ.S., BaeS.H., YoonS.K., ChoiI.B., KangK.M., JangH.S.: Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.Int J Radiat Oncol Biol Phys, 78: 1073–1080, 2010.
